Cardiac Effects in Long-Term Survivors of Hodgkin's and Non-Hodgkin's Lymphoma
Completed
- Conditions
- Hodgkin DiseaseLymphoma, Non-Hodgkin
- Registration Number
- NCT00903890
- Lead Sponsor
- University of Rochester
- Brief Summary
This study is to inquire by mailed survey regarding the cardiac and general health of patients previously treated for Hodgkin's and non-Hodgkin's lymphoma with radiation therapy/anthracycline chemotherapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 32
Inclusion Criteria
- All patients with Hodgkin's Lymphoma and Non Hodgkin's lymphoma who underwent Radiation Therapy (RT) to either a mantle or modified mantle field with or without adriamycin at the Wilmot Cancer Center at the University of Rochester are eligible for the study.
Exclusion Criteria
- Any severe preexisting cardiac disease (e.g., arrhythmia, angina, coronary disease, myocardial infarction, or congestive heart failure) prior to diagnosis
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Measure changes in Cardiac ejection fraction score Post Radiation Treatment Measure changes in perfusion imaging score on the radionuclide cardiac profusion scan Post Radiation
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link anthracycline chemotherapy to long-term cardiac effects in lymphoma survivors?
How does radiation therapy impact cardiac outcomes compared to anthracycline-based regimens in Hodgkin's and Non-Hodgkin's lymphoma survivors?
Are there specific biomarkers that identify lymphoma patients at higher risk for cardiotoxicity from anthracyclines or radiation therapy?
What are the most effective strategies for managing anthracycline-induced cardiotoxicity in long-term lymphoma survivors?
How do combination approaches of radiation therapy and anthracyclines influence cardiac health in lymphoma patients compared to monotherapy or newer treatment modalities?
Trial Locations
- Locations (1)
University of Rochester Medical Center
🇺🇸Rochester, New York, United States
University of Rochester Medical Center🇺🇸Rochester, New York, United States